- life sciences/pharma sector
-
2nd Annual Predictive Toxicology
Improve predictive modelling success and explore alternatives to testing in accordance with regulatory guidelines
Event Date: 2-3 Sep 2010
Location: Hotel Palace Berlin, Germany
- key conference speakers
-
Dr. David Cook Associate Director, Global Safety Assessment, AstraZeneca Dr. Lolke de Haan Head of Toxicology, Biologics Safety Assessment, MedImmune Dr. Eckhard von Keutz Senior Vice President and Head of Global Early Development , Bayer Schering Pharma AG Dr. Francois Pognan Director of Biochemical and Organ Toxicity, Novartis Dr. Donna Mendrick Director, Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration (FDA)
- key conference topics
-
- AstraZeneca reviewing the advancements in in silico techniques for drug discovery
- MedImmune examines the issues in interpreting predictive toxicology studies and approaches to dose selection
- Novartis profiling high-content cellular imaging approach for in vitro toxicology
- Sanofi-Aventis evaluating the use of cardiotoxicity biomarkers
- Bayer Schering Pharma AG discussing tackling the interface between toxicology and pharmacovigilance
- conference focus
-
Predictive toxicology is the first step in developing any viable drug on the market Predictive toxicology is the first step in developing any viable drug on the market. Toxicology testing has evolved greatly to incorporate the possibility of using alternatives to animal models and the application of biomarkers to evaluate adverse effects. There is also cutting-edge research into areas such as CNS and cardiovascular disease. By understanding technological advances in how to best use in vitro and in silico methods to better predict in vivo results, a company can cost effectively develop drugs that will ensure market survival.
This 2nd annual marcus evans conference will provide valuable knowledge to enhance drug development strategies by profiling novel solutions for toxicology screening with the latest predictive tools. Attendees will receive key industry and regulatory insights on overcoming regulatory pressures in achieving approval on biomarker use for models and qualification of data on products. The use of outsourced contract research organisations (CROs) will be evaluated which in turn will provide analysis on minimising costs and improving data quality to ensure business success.